MAIA Advances Phase 3 THIO-104 Trial Of Ateganosine In NSCLC, Targets 100 Patients By Year-End

MAIA Biotechnology provided a patient enrollment update for its pivotal Phase 3 THIO-104 trial of Ateganosine in third-line treatment for advanced non-small cell lung cancer. The update is operational and clinical in nature, with no efficacy, safety, or regulatory results disclosed. The news is modestly relevant for tracking trial progress but is unlikely to materially move the broader market.

Analysis

MAIA Biotechnology provided a patient enrollment update for its pivotal Phase 3 THIO-104 trial of Ateganosine in third-line treatment for advanced non-small cell lung cancer. The update is operational and clinical in nature, with no efficacy, safety, or regulatory results disclosed. The news is modestly relevant for tracking trial progress but is unlikely to materially move the broader market.